In vitro activity of four fluoroquinolones against clinical isolates of Pseudomonas aeruginosa determined by the E test

International Journal of Antimicrobial Agents

Volumn 15, Issue 1, 2000, Pages 73-76

  Swiatlo, E ^a,b   Moore, E ^b   Watt, J ^b   McDaniel, L S ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

E test; Fluoroquinolones; Pseudomonas aeruginosa; Susceptibility testing

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 0034037099     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00132-1     Document Type: Article

References (20)

1. Bodey G.P., Bolivar R., Fainstein V., Jadeja L. Infections caused by P. aeruginosa. Rev. Infect. Dis. 5:1983;279-313.
2. Blondeau J.M., Yaschuk Y., Suter M., Vaughan D. In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian antimicrobial study group. J. Antimicrob. Chemother. 43(suppl. A):1999;3-23.
3. Jarlier V., Fosse T., Phillippon A. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med. 22:1996;1057-1065.
4. Trupl J., Kunova A., Oravcova E. et al. Resistance pattern of 2816 isolates isolated from 17631 blood cultures and etiology of bacteremia and fungemia in a single cancer institution. Acta. Oncol. 36:1997;643-649.
5. Taccetti G., Campana S., Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian group for cystic fibrosis microbiology. Eur. J. Epidemiol. 15:1999;85-88.
6. Hooper D.C. Clinical applications of quinolones. Biochim. Biophys. Acta. 1400:1998;45-61.
7. Thomson C.J. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J. Antimicrob. Chemother. 43(Suppl. A):1999;31-40.
8. Fuchs P.C., Barry A.L., Brown S.D. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and resistant clinical bacterial isolates and assessment of the trovafloxacin disk test. Diagn. Microbiol. Infect. Dis. 33:1999;33-38.
9. Blondeau J.M., Suter M.E., Borsos S., Misfeldt C. Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin. Int. J. Antimicrob. Agents. 10:1998;297-302.
10. Peterson L.R., Postelnick M., Pozdol T.L., Reisberg B., Noskin G.A. Management of fluoroquinolone resistance in Pseudomonas aeruginosa - outcome of monitored use in a referral hospital. Int. J. Antimicrob. Agents. 10:1998;207-214.
11. Piddock L.J., Johnson M., Ricci V., Hill S.L. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42:1998;2956-2960.
12. Isenberg H.D., Alperstein P., France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn. Microbiol. Infect. Dis. 33:1999;81-86.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. NCCLS document M100-S9, NCCLS, Wayne, PA, 1999.
14. Baker C.N., Stocker S.A., Culver D.H., Thornsberry C. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J. Clin. Microbiol. 29:1991;533-538.
15. Huang M., Baker P.N., Banerjee S., Tenover F.C. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J. Clin. Microbiol. 30:1992;3243-3248.
16. Hoogkamp-Korstanje J.A. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J. Antimicrob. Chemother. 40:1997;427-431.
17. Mascellino M.T., Farinelli S., Iegri F., Iona E., De Simone C. Antimicrobial activity of fluoroquinolones and other antibiotics on 1116 clinical gram-positive and gram-negative isolates. Drugs Exp. Clin. Res. 24:1998;139-151.
18. Flynn C.M., Johnson D.M., Jones R.N. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J. Chemother. 8:1996;411-415.
19. Visalli M.A., Bajaksouzian S., Jacobs M.R., Appelbaum P.C. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1997;1475-1481.
20. Segatore B., Setacci D., Perilli M. et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1999;428-431.